{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:25:47Z","timestamp":1766579147558,"version":"3.37.3"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40123-023-00767-0","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T14:01:37Z","timestamp":1689948097000},"page":"2295-2321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Shaping the Future of Beh\u00e7et\u2019s Uveitis Management: A Comprehensive Review of Efficacy, Challenges, and Prospects of Biologic Therapies"],"prefix":"10.1007","volume":"12","author":[{"given":"Biao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2570-1703","authenticated-orcid":false,"given":"Yanlin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"issue":"3","key":"767_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas HH, Urgancioglu M. Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373\u201380.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"767_CR2","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/rheumatology\/ker428","volume":"51","author":"C Maldini","year":"2012","unstructured":"Maldini C, Lavalley M, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet\u2019s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5):887\u2013900. https:\/\/doi.org\/10.1093\/rheumatology\/ker428.","journal-title":"Rheumatology (Oxford)"},{"key":"767_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fimmu.2019.01067","volume":"10","author":"P Leccese","year":"2019","unstructured":"Leccese P, Alpsoy E. Beh\u00e7et\u2019s disease: an overview of etiopathogenesis. Front Immunol. 2019;10:1067. https:\/\/doi.org\/10.3389\/fimmu.2019.01067.","journal-title":"Front Immunol"},{"issue":"3","key":"767_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373\u201380. https:\/\/doi.org\/10.1016\/j.ajo.2004.03.022.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"767_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik A, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"767_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-021-01011-z","volume":"23","author":"F Alibaz-Oner","year":"2021","unstructured":"Alibaz-Oner F, Direskeneli H. Advances in the treatment of Behcet\u2019s disease. Curr Rheumatol Rep. 2021;23(6):47. https:\/\/doi.org\/10.1007\/s11926-021-01011-z.","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"767_CR7","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Mesquida M, Ad\u00e1n A, et al. Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/keu266.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"767_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/bjophthalmol-2012-302515","volume":"97","author":"T Sakai","year":"2013","unstructured":"Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, et al. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis. Br J Ophthalmol. 2013;97(3):338\u201342. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302515.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"767_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/iovs.02-0199","volume":"44","author":"N Rao","year":"2003","unstructured":"Rao N, Kimoto T, Zamir E, Giri R, Wang R, Ito S, et al. Pathogenic role of retinal microglia in experimental uveoretinitis. Invest Ophthalmol Vis Sci. 2003;44(1):22\u201331. https:\/\/doi.org\/10.1167\/iovs.02-0199.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"767_CR10","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1186\/ar3824","volume":"14","author":"S Sugita","year":"2012","unstructured":"Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet\u2019s disease. Arthritis Res Ther. 2012;14(3):R99.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"767_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejr.2014.01.004","volume":"36","author":"M El Menyawi","year":"2014","unstructured":"El Menyawi M, Fawzy M, Al-Nahas Z, Edris A, Hussein H, Shaker O, et al. Serum tumor necrosis factor alpha (TNF-\u03b1) level in patients with Beh\u00e7et\u2019s disease: relation to clinical manifestations and disease activity. Egypt Rheumatol. 2014;36(3):139\u201343. https:\/\/doi.org\/10.1016\/j.ejr.2014.01.004.","journal-title":"Egypt Rheumatol"},{"issue":"2","key":"767_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","volume":"139","author":"A El-Asrar","year":"2011","unstructured":"El-Asrar A, Struyf S, Kangave D, Al-Obeidan S, Opdenakker G, Geboes K, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol (Orlando, FL). 2011;139(2):177\u201384. https:\/\/doi.org\/10.1016\/j.clim.2011.01.014.","journal-title":"Clin Immunol (Orlando, FL)"},{"issue":"2","key":"767_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09629350220131935","volume":"11","author":"C Evereklioglu","year":"2002","unstructured":"Evereklioglu C, Er H, T\u00fcrk\u00f6z Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease. Mediat Inflamm. 2002;11(2):87\u201393. https:\/\/doi.org\/10.1080\/09629350220131935.","journal-title":"Mediat Inflamm"},{"issue":"1","key":"767_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/09273948.2016.1158276","volume":"25","author":"M Takeuchi","year":"2017","unstructured":"Takeuchi M, Karasawa Y, Harimoto K, Tanaka A, Shibata M, Sato T, et al. Analysis of Th cell-related cytokine production in behcet disease patients with uveitis before and after infliximab treatment. Ocul Immunol Inflamm. 2017;25(1):52\u201361. https:\/\/doi.org\/10.3109\/09273948.2016.1158276.","journal-title":"Ocul Immunol Inflamm"},{"key":"767_CR15","doi-asserted-by":"publisher","first-page":"912906","DOI":"10.3389\/fphar.2022.912906","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Shi X, Ren Y, Yan T, Ye Q. Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with Beh\u00e7et\u2019s disease: a systematic review of controlled trials. Front Pharmacol. 2022;13:912906. https:\/\/doi.org\/10.3389\/fphar.2022.912906.","journal-title":"Front Pharmacol"},{"issue":"5","key":"767_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.18240\/ijo.2022.05.19","volume":"15","author":"S Abolhasani","year":"2022","unstructured":"Abolhasani S, Khabbazi A, Hosseini F, Gholizadeh-Ghaleh Aziz S, Alipour S. Effects of anti-TNF biologic drugs on uveitis severity in Beh\u00e7et patients: systematic review and meta-analysis. Int J Ophthalmol. 2022;15(5):813\u20139. https:\/\/doi.org\/10.18240\/ijo.2022.05.19.","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"767_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"P Sfikakis","year":"2004","unstructured":"Sfikakis P, Kaklamanis P, Elezoglou A, Katsilambros N, Theodossiadis P, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease. Ann Intern Med. 2004;140(5):404\u20136. https:\/\/doi.org\/10.7326\/0003-4819-140-5-200403020-00025.","journal-title":"Ann Intern Med"},{"issue":"6","key":"767_CR18","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-018-4092-4","volume":"37","author":"C Fabiani","year":"2018","unstructured":"Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Sota J, et al. Predictors of sustained clinical response in patients with Behcet\u2019s disease-related uveitis treated with infliximab and adalimumab. Clin Rheumatol. 2018;37(6):1715\u201320. https:\/\/doi.org\/10.1007\/s10067-018-4092-4.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"767_CR19","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain A, Gul A, et al. EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis. 2008;67(12):1656\u201362. https:\/\/doi.org\/10.1136\/ard.2007.080432.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"767_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s10384-010-0824-y","volume":"54","author":"T Sakai","year":"2010","unstructured":"Sakai T, Kanetaka A, Noro T, Tsuneoka H. Intraocular surgery in patients receiving infliximab therapy for Beh\u00e7et disease. Jpn J Ophthalmol. 2010;54(4):360.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"767_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4274\/tjo.galenos.2019.60308","volume":"50","author":"OP Cakar","year":"2020","unstructured":"Cakar OP. Behcet\u2019s uveitis: current diagnostic and therapeutic approach. Turk J Ophthalmol. 2020;50(3):169\u201382. https:\/\/doi.org\/10.4274\/tjo.galenos.2019.60308.","journal-title":"Turk J Ophthalmol"},{"issue":"2","key":"767_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/bjo.2009.168856","volume":"95","author":"Y Yamada","year":"2011","unstructured":"Yamada Y, Sugita S, Tanaka H, Kamoi K, Takase H, Mochizuki M. Timing of recurrent uveitis in patients with Behcet\u2019s disease receiving infliximab treatment. Br J Ophthalmol. 2011;95(2):205\u20138. https:\/\/doi.org\/10.1136\/bjo.2009.168856.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"767_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140(5):404\u20136. https:\/\/doi.org\/10.7326\/0003-4819-140-5-200403020-00025.","journal-title":"Ann Intern Med"},{"issue":"12","key":"767_CR24","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","volume":"57","author":"Y Ozguler","year":"2018","unstructured":"Ozguler Y, Leccese P, Christensen R, Esatoglu S, Bang D, Bodaghi B, et al. Management of major organ involvement of Beh\u00e7et\u2019s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford). 2018;57(12):2200\u201312. https:\/\/doi.org\/10.1093\/rheumatology\/key242.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"767_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3899\/jrheum.200300","volume":"48","author":"J Mart\u00edn-Varillas","year":"2021","unstructured":"Mart\u00edn-Varillas J, Atienza-Mateo B, Calvo-Rio V, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Ad\u00e1n A, et al. Long-term follow-up and optimization of infliximab in refractory uveitis due to Beh\u00e7et disease: national study of 103 white patients. J Rheumatol. 2021;48(5):741\u201350. https:\/\/doi.org\/10.3899\/jrheum.200300.","journal-title":"J Rheumatol"},{"issue":"1","key":"767_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09273948.2020.1774907","volume":"30","author":"H K\u00f6se","year":"2022","unstructured":"K\u00f6se H, Yal\u00e7\u0131nda\u011f N. Clinical follow-up of patients with Beh\u00e7et uveitis after discontinuation of infliximab therapy. Ocul Immunol Inflamm. 2022;30(1):203\u20137. https:\/\/doi.org\/10.1080\/09273948.2020.1774907.","journal-title":"Ocul Immunol Inflamm"},{"issue":"9278","key":"767_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease. Lancet. 2001;358(9278):295\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(01)05497-6.","journal-title":"Lancet"},{"issue":"7","key":"767_CR28","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s disease with refractory uveoretinitis. J Rheumatol. 2004;31(7):1362\u20138.","journal-title":"J Rheumatol"},{"issue":"9","key":"767_CR29","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/eye.2014.138","volume":"28","author":"H Keino","year":"2014","unstructured":"Keino H, Okada AA, Watanabe T, Taki W. Long-term efficacy of infliximab on background vascular leakage in patients with Behcet\u2019s disease. Eye (Lond). 2014;28(9):1100\u20136. https:\/\/doi.org\/10.1038\/eye.2014.138.","journal-title":"Eye (Lond)"},{"issue":"11","key":"767_CR30","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1136\/bjophthalmol-2020-316892","volume":"105","author":"H Keino","year":"2021","unstructured":"Keino H, Watanabe T, Nakayama M, Komagata Y, Fukuoka K, Okada A. Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Beh\u00e7et\u2019s disease. Br J Ophthalmol. 2021;105(11):1525\u201333. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316892.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"767_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10792-022-02495-z","volume":"43","author":"S Yamana","year":"2023","unstructured":"Yamana S, Hasegawa E, Takeda A, Yawata N, Sonoda K. Long-term outcomes of infliximab in patients with Beh\u00e7et\u2019s disease-associated uveitis. Int Ophthalmol. 2023;43(3):937\u201344. https:\/\/doi.org\/10.1007\/s10792-022-02495-z.","journal-title":"Int Ophthalmol"},{"issue":"3","key":"767_CR32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","volume":"50","author":"N Markomichelakis","year":"2011","unstructured":"Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis P. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et\u2019s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50(3):593\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keq366.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"767_CR33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","volume":"146","author":"KF Tabbara","year":"2008","unstructured":"Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease. Am J Ophthalmol. 2008;146(6):845-50.e1.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"767_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol. 2010;94(3):284\u20138. https:\/\/doi.org\/10.1136\/bjo.2009.158840.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"767_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00296-018-4193-z","volume":"39","author":"A Urruticoechea-Arana","year":"2019","unstructured":"Urruticoechea-Arana A, Cobo-Ibanez T, Villaverde-Garcia V, Santos Gomez M, Loza E, Vargas-Osorio K, et al. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behcet\u2019s disease associated uveitis: a systematic review. Rheumatol Int. 2019;39(1):47\u201358. https:\/\/doi.org\/10.1007\/s00296-018-4193-z.","journal-title":"Rheumatol Int"},{"issue":"3","key":"767_CR36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","volume":"154","author":"N Markomichelakis","year":"2012","unstructured":"Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Beh\u00e7et disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154(3):534-41.e1.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"767_CR37","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","volume":"36","author":"MM Hamza","year":"2016","unstructured":"Hamza MM, Macky TA, Sidky MK, Ragab G, Soliman MM. Intravitreal infliximab in refractory uveitis in Behcet\u2019s disease: a safety and efficacy clinical study. Retina. 2016;36(12):2399\u2013408. https:\/\/doi.org\/10.1097\/IAE.0000000000001109.","journal-title":"Retina"},{"issue":"8","key":"767_CR38","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1097\/iae.0000000000003095","volume":"41","author":"M Refaat","year":"2021","unstructured":"Refaat M, Abdullatif A, Hamza M, Macky T, El-Agha M, Ragab G, et al. Monthly intravitreal infliximab in Beh\u00e7et\u2019s disease active posterior uveitis: a long-term safety study. Retina (Philadelphia, PA). 2021;41(8):1739\u201347. https:\/\/doi.org\/10.1097\/iae.0000000000003095.","journal-title":"Retina (Philadelphia, PA)"},{"issue":"1","key":"767_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1574886310666151014114925","volume":"11","author":"P Neri","year":"2016","unstructured":"Neri P, Arapi I, Nicolai M, Pirani V, Saitta A, Luchetti MM, et al. Biologic therapy in inflammatory eye conditions (ophtalmology): safety profile. Curr Drug Saf. 2016;11(1):47\u201354. https:\/\/doi.org\/10.2174\/1574886310666151014114925.","journal-title":"Curr Drug Saf"},{"issue":"1","key":"767_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5152\/eurjrheum.2017.17068","volume":"5","author":"S Ueda","year":"2018","unstructured":"Ueda S, Akahoshi M, Takeda A, Inoue Y, Omoto A, Ayano M, et al. Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behcet\u2019s disease. Eur J Rheumatol. 2018;5(1):9\u201315. https:\/\/doi.org\/10.5152\/eurjrheum.2017.17068.","journal-title":"Eur J Rheumatol"},{"issue":"4","key":"767_CR41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/bjo.2009.174888","volume":"95","author":"S Sugita","year":"2011","unstructured":"Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol. 2011;95(4):549\u201352. https:\/\/doi.org\/10.1136\/bjo.2009.174888.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"767_CR42","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/09273948.2013.779727","volume":"21","author":"S Al Rashidi","year":"2013","unstructured":"Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21(6):468\u201374. https:\/\/doi.org\/10.3109\/09273948.2013.779727.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"767_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","volume":"27","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, et al. Ten-year retention rate of infliximab in patients with Behcet\u2019s disease-related uveitis. Ocul Immunol Inflamm. 2019;27(1):34\u20139. https:\/\/doi.org\/10.1080\/09273948.2017.1391297.","journal-title":"Ocul Immunol Inflamm"},{"issue":"Suppl 108","key":"767_CR44","first-page":"86","volume":"35","author":"G Guzelant","year":"2017","unstructured":"Guzelant G, Ucar D, Esatoglu SN, Hatemi G, Ozyazgan Y, Yurdakul S, et al. Infliximab for uveitis of Behcet\u2019s syndrome: a trend for earlier initiation. Clin Exp Rheumatol. 2017;35(Suppl 108):86\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl 5","key":"767_CR45","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","volume":"51","author":"A Rubbert-Roth","year":"2012","unstructured":"Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51(suppl 5):v38-47. https:\/\/doi.org\/10.1093\/rheumatology\/kes114.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"767_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","volume":"21","author":"S Ohno","year":"2019","unstructured":"Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21(1):2. https:\/\/doi.org\/10.1186\/s13075-018-1793-7.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"767_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et\u2019s disease. Autoimmun Rev. 2015;14(1):1\u20139.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"767_CR48","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","volume":"68","author":"H Vallet","year":"2016","unstructured":"Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthrit Rheumatol. 2016;68(6):1522\u201330. https:\/\/doi.org\/10.1002\/art.39667.","journal-title":"Arthrit Rheumatol"},{"key":"767_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000336187","volume-title":"New treatments in noninfectious uveitis","author":"J Gueudry","year":"2012","unstructured":"Gueudry J, LeHoang P, Bodaghi B. Anti-tumor necrosis factor-\u03b1 agents in noninfectious uveitis. In: New treatments in noninfectious uveitis. Karger Publishers; 2012. p. 63\u201378."},{"issue":"3","key":"767_CR50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3109\/09273948.2014.990041","volume":"24","author":"RN Hamam","year":"2016","unstructured":"Hamam RN, Barikian AW, Antonios RS, Abdulaal MR, Alameddine RM, El Mollayess G, et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocul Immunol Inflamm. 2016;24(3):319\u201326. https:\/\/doi.org\/10.3109\/09273948.2014.990041.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4 Suppl 67","key":"767_CR51","first-page":"S54","volume":"29","author":"I Olivieri","year":"2011","unstructured":"Olivieri I, Leccese P, D\u2019angelo S, Padula A, Nigro A, Palazzi C, et al. Efficacy of adalimumab in patients with Beh\u00e7et\u2019s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S54\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"767_CR52","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1080\/09273948.2017.1335756","volume":"26","author":"WJ Kheir","year":"2018","unstructured":"Kheir WJ, Mehanna CJ, Abdul Fattah M, Al Ghadban S, El Sabban M, Mansour AM, et al. Intravitreal adalimumab for the control of breakthrough intraocular inflammation. Ocul Immunol Inflamm. 2018;26(8):1206\u201311. https:\/\/doi.org\/10.1080\/09273948.2017.1335756.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"767_CR53","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"B Mushtaq","year":"2007","unstructured":"Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet\u2019s disease. Eye (Lond). 2007;21(6):824\u20135. https:\/\/doi.org\/10.1038\/sj.eye.6702352.","journal-title":"Eye (Lond)"},{"key":"767_CR54","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1791346","author":"K Kunimi","year":"2020","unstructured":"Kunimi K, Usui Y, Asakage M, Maehara C, Tsubota K, Mitsuhashi R, et al. Anti-TNF-\u03b1 therapy for refractory uveitis associated with Beh\u00e7et\u2019s syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm. 2020. https:\/\/doi.org\/10.1080\/09273948.2020.1791346.","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"767_CR55","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","volume":"51","author":"D Perra","year":"2012","unstructured":"Perra D, Alba MA, Callejas JL, Mesquida M, R\u00edos-Fern\u00e1ndez R, Adan A, et al. Adalimumab for the treatment of Beh\u00e7et\u2019s disease: experience in 19 patients. Rheumatology. 2012;51(10):1825\u201331.","journal-title":"Rheumatology"},{"issue":"4","key":"767_CR56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","volume":"97","author":"EB Suhler","year":"2013","unstructured":"Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97(4):481\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302292.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"767_CR57","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932\u201343.","journal-title":"N Engl J Med"},{"issue":"10050","key":"767_CR58","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/s0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet (Lond, Engl). 2016;388(10050):1183\u201392. https:\/\/doi.org\/10.1016\/s0140-6736(16)31339-3.","journal-title":"Lancet (Lond, Engl)"},{"issue":"7","key":"767_CR59","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","volume":"125","author":"EB Suhler","year":"2018","unstructured":"Suhler EB, Ad\u00e1n A, Br\u00e9zin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075\u201387. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.039.","journal-title":"Ophthalmology"},{"key":"767_CR60","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/annrheumdis-2019-eular.1606","volume":"78","author":"B Atienza-Mateo","year":"2019","unstructured":"Atienza-Mateo B, Mart\u00edn-Varillas JL, Calvo-Ri\u00f3 V, Demetrio-Pablo R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease. National multicenter study of 177 cases. Ann Rheum Dis. 2019;78:814\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.1606.","journal-title":"Ann Rheum Dis"},{"key":"767_CR61","doi-asserted-by":"publisher","first-page":"609148","DOI":"10.3389\/fphar.2021.609148","volume":"12","author":"S Yang","year":"2021","unstructured":"Yang S, Huang Z, Hu Y, Zhang J, Liu X, Li H, et al. The efficacy of adalimumab as an initial treatment in patients with Beh\u00e7et\u2019s retinal vasculitis. Front Pharmacol. 2021;12:609148. https:\/\/doi.org\/10.3389\/fphar.2021.609148.","journal-title":"Front Pharmacol"},{"issue":"5","key":"767_CR62","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","volume":"102","author":"C Fabiani","year":"2018","unstructured":"Fabiani C, Sota J, Vitale A, Rigante D, Emmi G, Vannozzi L, et al. Cumulative retention rate of adalimumab in patients with Behcet\u2019s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102(5):637\u201341. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310733.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"767_CR63","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","volume":"31","author":"K Takase","year":"2011","unstructured":"Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y. Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis. Rheumatol Int. 2011;31(2):243\u20135. https:\/\/doi.org\/10.1007\/s00296-009-1178-y.","journal-title":"Rheumatol Int"},{"key":"767_CR64","doi-asserted-by":"publisher","first-page":"1623847","DOI":"10.1155\/2019\/1623847","volume":"2019","author":"A Bitossi","year":"2019","unstructured":"Bitossi A, Bettiol A, Silvestri E, Di Scala G, Bacherini D, Lopalco G, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediat Inflamm. 2019;2019:1623847. https:\/\/doi.org\/10.1155\/2019\/1623847.","journal-title":"Mediat Inflamm."},{"issue":"4","key":"767_CR65","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1517\/14740338.4.4.637","volume":"4","author":"N Scheinfeld","year":"2005","unstructured":"Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005;4(4):637\u201341. https:\/\/doi.org\/10.1517\/14740338.4.4.637.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"767_CR66","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1136\/ard.2009.116319","volume":"69","author":"E Keystone","year":"2010","unstructured":"Keystone E, Genovese M, Klareskog L, Hsia E, Hall S, Miranda P, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010;69(6):1129\u201335. https:\/\/doi.org\/10.1136\/ard.2009.116319.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"767_CR67","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1136\/annrheumdis-2011-200956","volume":"71","author":"J Smolen","year":"2012","unstructured":"Smolen J, Kay J, Landew\u00e9 R, Matteson E, Gaylis N, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis. 2012;71(10):1671\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200956.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"767_CR68","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/09273948.2012.741744","volume":"21","author":"M Mesquida","year":"2013","unstructured":"Mesquida M, Victoria Hernandez M, Llorenc V, Pelegrin L, Espinosa G, Dick AD, et al. Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21(2):160\u20132. https:\/\/doi.org\/10.3109\/09273948.2012.741744.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6 Supplement 10","key":"767_CR69","first-page":"S34","volume":"34","author":"M Santos-Gomez","year":"2016","unstructured":"Santos-Gomez M, Calvo-Rio V, Blanco R, Beltran E, Mesquida M, Adan A, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet\u2019s disease: results of a multicentre open-label study. Clin Exp Rheumatol. 2016;34(6 Supplement 102):S34\u201340.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"767_CR70","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s10067-017-3627-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G, Fabiani C, Gentileschi S, Silvestri E, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Beh\u00e7et\u2019s disease. Clin Rheumatol. 2017;36(9):2063\u20139.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"767_CR71","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/09273948.2017.1351573","volume":"27","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behcet\u2019s disease. Ocul Immunol Inflamm. 2019;27(1):58\u201363. https:\/\/doi.org\/10.1080\/09273948.2017.1351573.","journal-title":"Ocul Immunol Inflamm"},{"key":"767_CR72","doi-asserted-by":"publisher","first-page":"286857","DOI":"10.1155\/2013\/286857","volume":"2013","author":"D Sanchez-Cano","year":"2013","unstructured":"Sanchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Rios-Fernandez R, Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Behcet\u2019s disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm. 2013;2013:286857. https:\/\/doi.org\/10.1155\/2013\/286857.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"767_CR73","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98\u2013105.","journal-title":"J Rheumatol"},{"issue":"suppl 2","key":"767_CR74","doi-asserted-by":"publisher","first-page":"ii51","DOI":"10.1136\/ard.61.suppl_2.ii51","volume":"61","author":"P Sfikakis","year":"2002","unstructured":"Sfikakis P. Behcet\u2019s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61(suppl 2):ii51\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"767_CR75","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3899\/jrheum.110865","volume":"39","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39(2):233\u20139. https:\/\/doi.org\/10.3899\/jrheum.110865.","journal-title":"J Rheumatol"},{"issue":"12","key":"767_CR76","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","volume":"113","author":"A Galor","year":"2006","unstructured":"Galor A, Perez V, Hammel J, Lowder C. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113(12):2317\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2006.04.038.","journal-title":"Ophthalmology"},{"issue":"3","key":"767_CR77","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785-U215. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.048.","journal-title":"Ophthalmology"},{"key":"767_CR78","first-page":"54","volume":"1","author":"AK Reddy","year":"2015","unstructured":"Reddy AK, Albini TA. A review of biologics for uveitis. Retin Today. 2015;1:54\u20136.","journal-title":"Retin Today."},{"key":"767_CR79","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.imlet.2016.12.001","volume":"186","author":"N Gholijani","year":"2017","unstructured":"Gholijani N, Ataollahi MR, Samiei A, Aflaki E, Shenavandeh S, Kamali-Sarvestani E. An elevated pro-inflammatory cytokines profile in Behcet\u2019s disease: a multiplex analysis. Immunol Lett. 2017;186:46\u201351. https:\/\/doi.org\/10.1016\/j.imlet.2016.12.001.","journal-title":"Immunol Lett"},{"issue":"9","key":"767_CR80","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1167\/iovs.06-0058","volume":"47","author":"J Plskova","year":"2006","unstructured":"Plskova J, Greiner K, Muckersie E, Duncan L, Forrester J. Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci. 2006;47(9):3946\u201350. https:\/\/doi.org\/10.1167\/iovs.06-0058.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"767_CR81","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1167\/iovs.18-25548","volume":"60","author":"O Albayrak","year":"2019","unstructured":"Albayrak O, Oray M, Can F, Uludag Kirimli G, Gul A, Tugal-Tutkun I, et al. Effect of interferon alfa-2a treatment on adaptive and innate immune systems in patients with Behcet disease uveitis. Invest Ophthalmol Vis Sci. 2019;60(1):52\u201363. https:\/\/doi.org\/10.1167\/iovs.18-25548.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"767_CR82","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3349\/ymj.2015.56.4.1158","volume":"56","author":"JY Park","year":"2015","unstructured":"Park JY, Chung YR, Lee K, Song JH, Lee ES. Clinical experience of interferon Alfa-2a treatment for refractory uveitis in Behcet\u2019s disease. Yonsei Med J. 2015;56(4):1158\u201362. https:\/\/doi.org\/10.3349\/ymj.2015.56.4.1158.","journal-title":"Yonsei Med J"},{"key":"767_CR83","first-page":"320","volume-title":"Seminars in arthritis and rheumatism","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N. The use of interferon \u03b1 in Beh\u00e7et disease: review of the literature. In: Seminars in arthritis and rheumatism. Elsevier; 2004. p. 320\u201335."},{"issue":"1","key":"767_CR84","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/09273948.2017.1384026","volume":"27","author":"P Yang","year":"2019","unstructured":"Yang P, Huang G, Du L, Ye Z, Hu K, Wang C, et al. Long-term efficacy and safety of interferon Alpha-2a in the treatment of Chinese patients with Behcet\u2019s uveitis not responding to conventional therapy. Ocul Immunol Inflamm. 2019;27(1):7\u201314. https:\/\/doi.org\/10.1080\/09273948.2017.1384026.","journal-title":"Ocul Immunol Inflamm"},{"key":"767_CR85","doi-asserted-by":"publisher","first-page":"204062231984788","DOI":"10.1177\/2040622319847881","volume":"10","author":"J Shi","year":"2019","unstructured":"Shi J, Zhao C, Zhou J, Liu J, Wang L, Gao F, et al. Effectiveness and safety of interferon alpha2a as an add-on treatment for refractory Behcet\u2019s uveitis. Ther Adv Chronic Dis. 2019;10:2040622319847881. https:\/\/doi.org\/10.1177\/2040622319847881.","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"767_CR86","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","volume":"74","author":"S Lightman","year":"2015","unstructured":"Lightman S, Taylor SR, Bunce C, Longhurst H, Lynn W, Moots R, et al. Pegylated interferon-alpha-2b reduces corticosteroid requirement in patients with Behcet\u2019s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. 2015;74(6):1138\u201344. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205571.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"767_CR87","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"CM Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet\u2019s disease. Arthrit Rheum. 2010;62(9):2796\u2013805. https:\/\/doi.org\/10.1002\/art.27581.","journal-title":"Arthrit Rheum"},{"issue":"7","key":"767_CR88","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","volume":"117","author":"G Sobaci","year":"2010","unstructured":"Sobaci G, Erdem U, Durukan A, Erdurman C, Bayer A, K\u00f6ksal S, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh\u00e7et\u2019s uveitis refractory to conventional treatments. Ophthalmology. 2010;117(7):1430\u20135. https:\/\/doi.org\/10.1016\/j.ophtha.2009.11.022.","journal-title":"Ophthalmology"},{"issue":"11","key":"767_CR89","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s10067-016-3318-6","volume":"35","author":"H Kavandi","year":"2016","unstructured":"Kavandi H, Khabbazi A, Kolahi S, Hajialilo M, Shayan FK, Oliaei M. Long-term efficacy and safety of interferon \u03b1-2a therapy in severe refractory ophthalmic Behcet\u2019s disease. Clin Rheumatol. 2016;35(11):2765\u20139.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"767_CR90","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09273948.2015.1133835","volume":"25","author":"M Hasanreisoglu","year":"2017","unstructured":"Hasanreisoglu M, Cubuk MO, Ozdek S, Gurelik G, Aktas Z, Hasanreisoglu B. Interferon Alpha-2a therapy in patients with refractory Behcet uveitis. Ocul Immunol Inflamm. 2017;25(1):71\u20135. https:\/\/doi.org\/10.3109\/09273948.2015.1133835.","journal-title":"Ocul Immunol Inflamm"},{"key":"767_CR91","doi-asserted-by":"publisher","first-page":"699903","DOI":"10.3389\/fphar.2021.699903","volume":"12","author":"Y Qian","year":"2021","unstructured":"Qian Y, Qu Y, Gao F, Pei M, Liang A, Xiao J, et al. Comparison of the safety and efficacy of interferon Alpha-2a and cyclosporine-a when combined with glucocorticoid in the treatment of refractory Beh\u00e7et\u2019s uveitis: a randomized controlled prospective study. Front Pharmacol. 2021;12:699903. https:\/\/doi.org\/10.3389\/fphar.2021.699903.","journal-title":"Front Pharmacol"},{"issue":"1","key":"767_CR92","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/09273948.2016.1206204","volume":"25","author":"E Diwo","year":"2017","unstructured":"Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of interferon in severe uveitis associated with Behcet disease. Ocul Immunol Inflamm. 2017;25(1):76\u201384. https:\/\/doi.org\/10.1080\/09273948.2016.1206204.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"767_CR93","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","volume":"129","author":"S Onal","year":"2011","unstructured":"Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis. Arch Ophthalmol. 2011;129(3):288\u201394.","journal-title":"Arch Ophthalmol"},{"issue":"4 Suppl 84","key":"767_CR94","first-page":"S175","volume":"32","author":"Y Keskin","year":"2014","unstructured":"Keskin Y, Seyahi E, Poyraz C, Ugurlu S, Ozyazgan Y, Yazici H. Interferon alfa-associated depression in patients with Beh\u00e7et\u2019s syndrome: a prospective controlled study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S175.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"767_CR95","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633\u201352. https:\/\/doi.org\/10.1038\/nrd3800.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"767_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00296-003-0400-6","volume":"25","author":"N Duzgun","year":"2005","unstructured":"Duzgun N, Ayaslioglu E, Tutkak H, Aydintug OT. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet\u2019s disease. Rheumatol Int. 2005;25(1):1\u20135. https:\/\/doi.org\/10.1007\/s00296-003-0400-6.","journal-title":"Rheumatol Int"},{"issue":"9","key":"767_CR97","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/imj.13538","volume":"47","author":"I Orlando","year":"2017","unstructured":"Orlando I, Vitale A, Rigante D, Lopalco G, Fabiani C, Cantarini L. Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behcet disease uveitis and concomitant bladder papillary carcinoma. Intern Med J. 2017;47(9):1086\u20138. https:\/\/doi.org\/10.1111\/imj.13538.","journal-title":"Intern Med J"},{"issue":"2","key":"767_CR98","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/bjo.2006.0101477","volume":"91","author":"S Teoh","year":"2007","unstructured":"Teoh S, Sharma S, Hogan A, Lee R, Ramanan A, Dick A. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol. 2007;91(2):263\u20134. https:\/\/doi.org\/10.1136\/bjo.2006.0101477.","journal-title":"Br J Ophthalmol"},{"key":"767_CR99","first-page":"152","volume":"31","author":"G Emmi","year":"2013","unstructured":"Emmi G, Silvestri E, Cameli A, Bacherini D, Vannozzi L, Squatrito D, et al. Anakinra for resistant Beh\u00e7et uveitis: why not? Clin Exp Rheumatol. 2013;31:152\u20133.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"767_CR100","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series. Clin Rheumatol. 2015;34(7):1293\u2013301. https:\/\/doi.org\/10.1007\/s10067-013-2443-8.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"767_CR101","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"S Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet\u2019s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71(9):1589\u201391. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201383.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"767_CR102","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jmb.2012.09.021","volume":"425","author":"M Blech","year":"2013","unstructured":"Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, et al. One target\u2014two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1\u03b2. J Mol Biol. 2013;425(1):94\u2013111.","journal-title":"J Mol Biol"},{"issue":"Suppl 72","key":"767_CR103","first-page":"S115","volume":"30","author":"L Cantarini","year":"2012","unstructured":"Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R. Successful use of canakinumab in a patient with resistant Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2012;30(Suppl 72):S115.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"767_CR104","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191\u20137. https:\/\/doi.org\/10.1007\/s10067-016-3506-4.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"767_CR105","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","volume":"26","author":"L Kaly","year":"2012","unstructured":"Kaly L, Rosner I. Tocilizumab\u2014a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol. 2012;26(1):157\u201365.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"767_CR106","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T. IL-6: regulator of Treg\/Th17 balance. Eur J Immunol. 2010;40(7):1830\u20135.","journal-title":"Eur J Immunol"},{"issue":"3","key":"767_CR107","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","volume":"128","author":"G Geri","year":"2011","unstructured":"Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh\u00e7et disease. J Allergy Clin Immunol. 2011;128(3):655\u201364. https:\/\/doi.org\/10.1016\/j.jaci.2011.05.029.","journal-title":"J Allergy Clin Immunol"},{"key":"767_CR108","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2147\/OPTH.S68595","volume":"9","author":"P Lin","year":"2015","unstructured":"Lin P. Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 2015;9:1697\u2013702. https:\/\/doi.org\/10.2147\/OPTH.S68595.","journal-title":"Clin Ophthalmol"},{"key":"767_CR109","first-page":"88","volume-title":"Seminars in immunology","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. In: Seminars in immunology. Elsevier; 2014. p. 88\u201396."},{"key":"767_CR110","doi-asserted-by":"publisher","first-page":"946048","DOI":"10.1155\/2012\/946048","volume":"2012","author":"A Ogata","year":"2012","unstructured":"Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol. 2012;2012:946048. https:\/\/doi.org\/10.1155\/2012\/946048.","journal-title":"Int J Rheumatol"},{"issue":"3","key":"767_CR111","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/art.39940","volume":"69","author":"V Calvo-R\u00edo","year":"2017","unstructured":"Calvo-R\u00edo V, Santos-G\u00f3mez M, Calvo I, Gonz\u00e1lez-Fern\u00e1ndez MI, L\u00f3pez-Montesinos B, Mesquida M, et al. Anti\u2013interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthrit Rheumatol. 2017;69(3):668\u201375. https:\/\/doi.org\/10.1002\/art.39940.","journal-title":"Arthrit Rheumatol"},{"issue":"2","key":"767_CR112","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s10165-011-0497-5","volume":"22","author":"T Hirano","year":"2012","unstructured":"Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, et al. A case of Behcet\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22(2):298\u2013302. https:\/\/doi.org\/10.1007\/s10165-011-0497-5.","journal-title":"Mod Rheumatol"},{"key":"767_CR113","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","volume":"200","author":"N Vegas-Revenga","year":"2019","unstructured":"Vegas-Revenga N, Calvo-R\u00edo V, Mesquida M, Ad\u00e1n A, Hern\u00e1ndez M, Beltr\u00e1n E, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85\u201394. https:\/\/doi.org\/10.1016\/j.ajo.2018.12.019.","journal-title":"Am J Ophthalmol"},{"key":"767_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-320604","author":"M Hassan","year":"2022","unstructured":"Hassan M, Sadiq M, Ormaechea M, Uluda\u011f G, Halim M, Afridi R, et al. Utilisation of composite endpoint outcome to assess efficacy of tocilizumab for non-infectious uveitis in the STOP-uveitis study. Br J Ophthalmol. 2022. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-320604.","journal-title":"Br J Ophthalmol"},{"key":"767_CR115","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","volume":"183","author":"YJ Sepah","year":"2017","unstructured":"Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, et al. Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71\u201380. https:\/\/doi.org\/10.1016\/j.ajo.2017.08.019.","journal-title":"Am J Ophthalmol"},{"key":"767_CR116","doi-asserted-by":"publisher","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","volume":"5","author":"B Atienza-Mateo","year":"2021","unstructured":"Atienza-Mateo B, Beltr\u00e1n E, Hern\u00e1ndez-Garfella M, Valls Pascual E, Mart\u00ednez-Costa L, Atanes A, et al. Tocilizumab in Beh\u00e7et\u2019s disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes. Clin Exp Rheumatol. 2021;5:37\u201342. https:\/\/doi.org\/10.55563\/clinexprheumatol\/9ipkcs.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"767_CR117","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","volume":"50","author":"M Akiyama","year":"2020","unstructured":"Akiyama M, Kaneko Y, Takeuchi T. Effectiveness of tocilizumab in Behcet\u2019s disease: a systematic literature review. Semin Arthrit Rheum. 2020;50(4):797\u2013804. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.05.017.","journal-title":"Semin Arthrit Rheum"},{"issue":"8","key":"767_CR118","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.55563\/clinexprheumatol\/xnb396","volume":"40","author":"C Zhao","year":"2022","unstructured":"Zhao C, Liu J, Song H, Shi J, Zhang M, Zheng W. Anti-interleukin 6 receptor antibody tocilizumab was not satisfactory for acute attack of Beh\u00e7et\u2019s uveitis in three consecutive patients. Clin Exp Rheumatol. 2022;40(8):1600. https:\/\/doi.org\/10.55563\/clinexprheumatol\/xnb396.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"767_CR119","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777\u201387. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.040.","journal-title":"Ophthalmology"},{"issue":"1","key":"767_CR120","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00296-017-3775-5","volume":"38","author":"J Sota","year":"2018","unstructured":"Sota J, Rigante D, Lopalco G, Frediani B, Franceschini R, Galeazzi M, et al. Biological therapies for the treatment of Behcet\u2019s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatol Int. 2018;38(1):25\u201335. https:\/\/doi.org\/10.1007\/s00296-017-3775-5.","journal-title":"Rheumatol Int"},{"issue":"52","key":"767_CR121","doi-asserted-by":"publisher","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","volume":"2","author":"W Hueber","year":"2010","unstructured":"Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. https:\/\/doi.org\/10.1126\/scitranslmed.3001107.","journal-title":"Sci Transl Med."},{"issue":"5","key":"767_CR122","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","volume":"122","author":"E Letko","year":"2015","unstructured":"Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.033.","journal-title":"Ophthalmology"},{"key":"767_CR123","doi-asserted-by":"publisher","first-page":"380405","DOI":"10.1155\/2014\/380405","volume":"2014","author":"O Shaker","year":"2014","unstructured":"Shaker O, Tawfic S, El-Tawdy A, El-Komy M, El Menyawi M, Heikal A. Expression of TNF-\u03b1, APRIL and BCMA in Behcet\u2019s disease. J Immunol Res. 2014;2014:380405. https:\/\/doi.org\/10.1155\/2014\/380405.","journal-title":"J Immunol Res"},{"issue":"12","key":"767_CR124","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1007\/s00415-015-7897-y","volume":"262","author":"D Kidd","year":"2015","unstructured":"Kidd D. Rituximab is effective in severe treatment-resistant neurological Beh\u00e7et\u2019s syndrome. J Neurol. 2015;262(12):2676\u20137. https:\/\/doi.org\/10.1007\/s00415-015-7897-y.","journal-title":"J Neurol"},{"issue":"10","key":"767_CR125","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s10067-014-2781-1","volume":"34","author":"F Caso","year":"2015","unstructured":"Caso F, Rigante D, Vitale A, Costa L, Bascherini V, Latronico E, et al. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clin Rheumatol. 2015;34(10):1817\u201320. https:\/\/doi.org\/10.1007\/s10067-014-2781-1.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"767_CR126","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","volume":"11","author":"E Miserocchi","year":"2011","unstructured":"Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11(1):35\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2011.07.001.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"767_CR127","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s10165-008-0057-9","volume":"18","author":"S Sadreddini","year":"2008","unstructured":"Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behcet\u2019s disease with rituximab. Mod Rheumatol. 2008;18(3):306\u20138. https:\/\/doi.org\/10.1007\/s10165-008-0057-9.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"767_CR128","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246\u201352. https:\/\/doi.org\/10.1111\/j.1756-185X.2010.01546.x.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"767_CR129","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/jcp.47.4.313","volume":"47","author":"JR Salisbury","year":"1994","unstructured":"Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin\u2019s lymphomas. J Clin Pathol. 1994;47(4):313\u20137. https:\/\/doi.org\/10.1136\/jcp.47.4.313.","journal-title":"J Clin Pathol"},{"issue":"7","key":"767_CR130","doi-asserted-by":"publisher","first-page":"16414","DOI":"10.3390\/ijms160716414","volume":"16","author":"T Ruck","year":"2015","unstructured":"Ruck T, Bittner S, Wiendl H, Meuth S. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci. 2015;16(7):16414\u201339. https:\/\/doi.org\/10.3390\/ijms160716414.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"767_CR131","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/bjo.84.1.107","volume":"84","author":"AD Dick","year":"2000","unstructured":"Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol. 2000;84(1):107\u20139. https:\/\/doi.org\/10.1136\/bjo.84.1.107.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"767_CR132","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","volume":"42","author":"CM Lockwood","year":"2003","unstructured":"Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behcet\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford). 2003;42(12):1539\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/keg424.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"767_CR133","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3899\/jrheum.141344","volume":"42","author":"AJ Mohammad","year":"2015","unstructured":"Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DR. Alemtuzumab as remission induction therapy in Behcet disease: a 20-year experience. J Rheumatol. 2015;42(10):1906\u201313. https:\/\/doi.org\/10.3899\/jrheum.141344.","journal-title":"J Rheumatol"},{"issue":"1","key":"767_CR134","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/jc.2013-2201","volume":"99","author":"GH Daniels","year":"2014","unstructured":"Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99(1):80\u20139. https:\/\/doi.org\/10.1210\/jc.2013-2201.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"767_CR135","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s11739-022-03038-1","volume":"17","author":"A Vitale","year":"2022","unstructured":"Vitale A, Autoinflammatory Diseases Alliance (AIDA) Network, et al. Development and implementation of the AIDA International Registry for patients with Beh\u00e7et\u2019s disease. Intern Emerg Med. 2022;17(7):1977\u201386. https:\/\/doi.org\/10.1007\/s11739-022-03038-1. (Epub 2022 Jul 14. PMID: 35831701; PMCID: PMC9522756).","journal-title":"Intern Emerg Med"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00767-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-023-00767-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-023-00767-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T10:47:17Z","timestamp":1692614837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-023-00767-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1007\/s40123-023-00767-0","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"type":"print","value":"2193-8245"},{"type":"electronic","value":"2193-6528"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"3 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}